PE20091720A1 - Compuestos de benzopirano y benzoxepina como inhibidores de pi3k - Google Patents

Compuestos de benzopirano y benzoxepina como inhibidores de pi3k

Info

Publication number
PE20091720A1
PE20091720A1 PE2009000466A PE2009000466A PE20091720A1 PE 20091720 A1 PE20091720 A1 PE 20091720A1 PE 2009000466 A PE2009000466 A PE 2009000466A PE 2009000466 A PE2009000466 A PE 2009000466A PE 20091720 A1 PE20091720 A1 PE 20091720A1
Authority
PE
Peru
Prior art keywords
compounds
oxepine
dihydrobenzo
chlorophenyl
benzopyrane
Prior art date
Application number
PE2009000466A
Other languages
English (en)
Inventor
Steven Do
Richard Goldsmith
Tim Heffron
Aleksandr Kolesnikov
Steven Staben
Alan G Olivero
Michael Siu
Daniel P Sutherlin
Bing-Yan Zhu
Paul Goldsmith
Tracy Bayliss
Adrian FOLKES
Neil Pegg
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of PE20091720A1 publication Critical patent/PE20091720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZOXEPINA DE FORMULA (I) DONDE Z1 ES CR1 O N; Z2 ES CR2 O N; Z3 ES CR3 O N; Z4 ES CR4 O N; X1 Y X2 SON CADA UNO N, S O CR7, EN DONDE R1, R2, R3, R4 Y R7 SON CADA UNO H, F, -CN, -CF3, -NO2, ENTRE OTROS; A ES -C(=O)NR5R6, HETEROCICLILO(C3-C20), HETEROARILO(C6-C20), ENTRE OTROS, DONDE R5 ES H O ALQUILO(C1-C12); R6 ES ALQUILO(C1-C12), CARBOCICLILO(C3-C12), HETEROCICLILO(C3-C20), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N2-(2-CLOROFENIL-N2,N8,N8-TRIMETIL-4,5-DIHIDROBENZO[b]TIENO[2,3-d]OXEPINA-2,8-DICARBOXAMIDA, 7-ACETAMIDO-N-(2-CLOROFENIL-N-METIL-4,5-DIHIDROBENZO[b]TIENO[2,3-d]OXEPINA-2-CARBOXAMIDA, N2-(2-CLOROFENIL-N8-(3-(DIETILAMINO)PROPIL)-N2-METIL-4,5-DIHIDROBENZO[b]TIENO[2,3-d]OXEPINA-2,8-DICARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFATIDILINOSITOL 3-CINASA (PI3K) SIENDO UTILES PARA EL TRATAMIENTO DE CANCER DE MAMA, ADENOCARCINOMA PULMONAR, CANCER DE COLON
PE2009000466A 2008-03-31 2009-03-30 Compuestos de benzopirano y benzoxepina como inhibidores de pi3k PE20091720A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4082708P 2008-03-31 2008-03-31
US10222008P 2008-10-02 2008-10-02

Publications (1)

Publication Number Publication Date
PE20091720A1 true PE20091720A1 (es) 2009-11-26

Family

ID=40790991

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000466A PE20091720A1 (es) 2008-03-31 2009-03-30 Compuestos de benzopirano y benzoxepina como inhibidores de pi3k

Country Status (22)

Country Link
US (4) US7928248B2 (es)
EP (1) EP2276767B1 (es)
JP (1) JP5511786B2 (es)
KR (1) KR101626996B1 (es)
CN (1) CN102333779B (es)
AR (1) AR071112A1 (es)
AU (1) AU2009231885B2 (es)
BR (1) BRPI0910346A2 (es)
CA (1) CA2719032C (es)
CL (1) CL2009000780A1 (es)
DK (1) DK2276767T3 (es)
ES (1) ES2480994T3 (es)
HK (1) HK1147741A1 (es)
IL (1) IL208359A (es)
MX (1) MX2010010659A (es)
PE (1) PE20091720A1 (es)
PL (1) PL2276767T3 (es)
RU (1) RU2506267C2 (es)
SI (1) SI2276767T1 (es)
TW (1) TWI443102B (es)
WO (1) WO2009123971A1 (es)
ZA (1) ZA201007218B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
KR101626996B1 (ko) 2008-03-31 2016-06-02 제넨테크, 인크. 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
UY32748A (es) * 2009-07-02 2011-01-31 Novartis Ag 2-carboxamida-cicloamino-ureas
ES2444779T3 (es) 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP2592071B1 (en) * 2009-10-29 2019-09-18 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
KR102012398B1 (ko) 2009-11-05 2019-08-20 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
US9073940B2 (en) 2009-11-13 2015-07-07 Merck Serono Sa Tricyclic pyrazol amine derivatives
US9072783B2 (en) 2009-11-18 2015-07-07 Aridis Pharmaceuticals Highly dispersible powders, compositions and methods for preparation
CN103153300A (zh) 2010-08-11 2013-06-12 米伦纽姆医药公司 杂芳基化合物和其用途
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
EP2688891B1 (en) 2011-03-21 2017-11-15 F. Hoffmann-La Roche AG Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
AU2012262748B2 (en) 2011-05-27 2017-03-02 Lexicon Pharmaceuticals, Inc. 4H-thieno[3,2-c]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use
EP2814830A1 (en) 2012-02-17 2014-12-24 F.Hoffmann-La Roche Ag Tricyclic compounds and methods of use therefor
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
SI2870157T1 (en) 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S.A. SELECTIVE PI3K-DELTA INHIBITORS
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
AU2014230812B2 (en) 2013-03-13 2016-04-07 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP6454419B2 (ja) 2014-12-11 2019-01-16 ナトコ ファーマ リミテッド 抗癌剤としての７−（モルホリニル）−２−（Ｎ−ピペラジニル）メチルチエノ［２，３−ｃ］ピリジン誘導体
PL3277683T3 (pl) * 2015-03-30 2022-05-23 Jubilant Biosys Limited Trójpierścieniowe pochodne 1-(cyklo)alkilopirydyn-2-onu użyteczne w leczeniu raka
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
US10633354B2 (en) 2016-09-02 2020-04-28 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN111093666A (zh) 2017-07-18 2020-05-01 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
AU2018302179A1 (en) 2017-07-18 2020-02-13 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
JP2022517419A (ja) 2019-01-18 2022-03-08 ニューベイション・バイオ・インコーポレイテッド アデノシンアンタゴニストとしてのヘテロ環式化合物
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
CN114156414B (zh) * 2021-11-30 2024-05-31 合肥工业大学 一种高效稳定CsPbI3无机钙钛矿电池的制备方法
CN115403591A (zh) * 2022-10-08 2022-11-29 河南师范大学 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
DE19831878C2 (de) * 1998-07-17 2001-05-17 Aventis Pharma Gmbh Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1403256A4 (en) * 2001-06-05 2004-10-20 Fujisawa Pharmaceutical Co FUSED IMIDAZOLE DERIVATIVE
US20040082602A1 (en) 2002-07-19 2004-04-29 Hagen Timothy J. Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
CA2579279C (en) * 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Tricyclic thiazole derivatives as pi3 kinases
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
EP2054058B1 (en) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
KR101626996B1 (ko) 2008-03-31 2016-06-02 제넨테크, 인크. 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
BRPI0910346A2 (pt) 2015-10-06
US20110130363A1 (en) 2011-06-02
KR20100137551A (ko) 2010-12-30
US7928248B2 (en) 2011-04-19
HK1147741A1 (en) 2011-08-19
ZA201007218B (en) 2012-06-27
CA2719032A1 (en) 2009-10-08
US20140336154A1 (en) 2014-11-13
DK2276767T3 (da) 2014-07-14
US9309265B2 (en) 2016-04-12
CA2719032C (en) 2016-11-08
RU2506267C2 (ru) 2014-02-10
US20090247567A1 (en) 2009-10-01
AU2009231885A1 (en) 2009-10-08
MX2010010659A (es) 2010-10-26
AR071112A1 (es) 2010-05-26
WO2009123971A1 (en) 2009-10-08
JP2011517457A (ja) 2011-06-09
US20130123263A1 (en) 2013-05-16
TW200944531A (en) 2009-11-01
EP2276767A1 (en) 2011-01-26
CL2009000780A1 (es) 2010-01-15
US8846762B2 (en) 2014-09-30
RU2010143319A (ru) 2012-05-10
TWI443102B (zh) 2014-07-01
CN102333779A (zh) 2012-01-25
AU2009231885B2 (en) 2014-04-03
CN102333779B (zh) 2015-12-09
KR101626996B1 (ko) 2016-06-02
IL208359A (en) 2016-07-31
US8399690B2 (en) 2013-03-19
ES2480994T3 (es) 2014-07-29
PL2276767T3 (pl) 2014-09-30
IL208359A0 (en) 2010-12-30
JP5511786B2 (ja) 2014-06-04
SI2276767T1 (sl) 2014-08-29
EP2276767B1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
PE20091720A1 (es) Compuestos de benzopirano y benzoxepina como inhibidores de pi3k
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
PE20191817A1 (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201290260A1 (ru) Бензимидазол-имидазольные производные
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
EA201270339A1 (ru) Замещенные производные ксантина
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA201200247A1 (ru) Новые азагетероциклические соединения
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed